NAV

Fluoroazomycin arabinoside F-18

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Fluoroazomycin arabinoside F-18
DrugBank Accession Number
DB15134
Background

Fluoroazomycin arabinoside F-18 is under investigation in clinical trial NCT03257150 (A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer).

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 246.185
Monoisotopic: 246.062983101
Chemical Formula
C8H10FN3O5
Synonyms
  • 18F-FAZA
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
UG7I3Y42PV
CAS number
864084-85-5
InChI Key
LPZSRGRDVVGMMX-FJBGPTLJSA-N
InChI
InChI=1S/C8H10FN3O5/c9-3-4-5(13)6(14)7(17-4)11-2-1-10-8(11)12(15)16/h1-2,4-7,13-14H,3H2/t4-,5-,6+,7+/m1/s1/i9-1
IUPAC Name
(2S,3S,4S,5S)-2-[(¹⁸F)fluoromethyl]-5-(2-nitro-1H-imidazol-1-yl)oxolane-3,4-diol
SMILES
O[C@H]1[C@H](O)[C@H](O[C@@H]1C[18F])N1C=CN=C1[N+]([O-])=O

References

General References
Not Available
ChemSpider
2104828

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedDiagnosticBreast Neoplasms1
1Enrolling by InvitationDiagnosticNon-Rhabdo. Soft Tissue Sarcoma / Rhabdomyosarcomas1
1, 2TerminatedDiagnosticNeuroendocrine Tumors / Renal Cell Carcinoma (RCC)1
Not AvailableCompletedNot AvailableAggressive, recurrent Non-Hodgkin Lymphoma / Aggressive, refractory Non-Hodgkin's Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent High Grade B-Cell Lymphoma / Recurrent Malignant Neoplasm / Recurrent Plasma Cell Myeloma / Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Refractory Diffuse Large B Cell Lymphoma (DLBCL) / Refractory High Grade B-cell Lymphoma (HGBCL) / Refractory Malignant Neoplasm / Refractory Plasma Cell Myeloma / Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma1
Not AvailableRecruitingDiagnosticPancreatic Adenocarcinoma Locally Advanced / Pancreatic Adenocarcinoma Non-resectable / Unresectable Pancreatic Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility13.0 mg/mLALOGPS
logP-0.45ALOGPS
logP-0.19Chemaxon
logS-1.3ALOGPS
pKa (Strongest Acidic)12.45Chemaxon
pKa (Strongest Basic)-0.016Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area110.65 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity49.71 m3·mol-1Chemaxon
Polarizability20.67 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at May 20, 2019 14:52 / Updated at June 12, 2020 16:53